Matthew J. Matasar, MD, discusses how updates in the diffuse large B-cell lymphoma field have led to improved quality of life in patients.
Matthew J. Matasar, MD, chief of the Medical Oncology Service at Memorial Sloan Kettering Cancer Center Bergen, discusses how updates in the diffuse large B-cell lymphoma (DLBCL) field have led to improved quality of life in patients.
While the rituximab (Rituxan), cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) regimen is known to be the standard frontline treatment for this patient population, experts like Matasar are always wanting to improve on the combination and see if any other standard of care option could be better.
The ongoing POLARIX trial (NCT03274492) looks to examine polatuzumab vedotin (Polivy) with rituximab, cyclophosphamide, doxorubicin and prednisone (Pola-R-CHP) and compare it to R-CHOP therapy in patients with previously untreated DLBCL. While there has yet to be data reported regarding the overall survival differences for patients using Pola-R-CHP, there was a 7% improvement in progression-free survival in patients with higher risk, DLBCL.
Transcription:
0:08 | There’s been ongoing efforts over the past decades to try to improve our treatment of patients with a new diagnosis of diffuse large B-cell lymphoma. There has been a lot of trouble improving beyond the standard of care of R-CHOP chemo immunotherapy. Although there have been many efforts over these years to try to do so, they have been unsuccessful. We now have our first positive clinical trial for patients with a new diagnosis of DLBCL in the form of the comparison of polatuzumab vedotin [Polivy] plus R-CHP chemotherapy versus R-CHOP chemotherapy, the so-called POLARIX trial.
0:50 | This was a randomized double blinded trial of the novel regimen against the R-CHOP standard of care for patients with higher risk diffuse large B-cell lymphoma. We found that indeed, inclusion of polatuzumab substitution of it for vincristine in the standard regimen led to an improvement in progression free survival of about 7% in patients with higher risk diffuse large B-cell lymphoma. This hasn’t yet translated to an overall survival difference, but a clinically and statistically significant improvement in PFS is something that's important for lymphoma specialists, oncologists, and patients to be aware of.
Challenges for Non–CAR T-Cell Treatment of Early Relapsed DLBCL
April 18th 2024During a Case-Based Roundtable® event, Elizabeth A. Brém, MD, discussed treatment approaches for a patient with early relapsed or primary refractory diffuse large B-cell lymphoma in the first article of a 2-part series.
Read More
Glofitamab Plus Chemo Improves Survival vs Rituximab in R/R DLBCL
April 16th 2024The phase 3 STARGLO trial met its primary end point, improving overall survival in patients with relapsed/refractory diffuse large B-cell lymphoma with glofitamab and chemotherapy vs rituximab and chemotherapy.
Read More
Comparing Results with Loncastuximab in the Clinic and Real-World Settings in DLBCL
April 1st 2024During a Case-Based Roundtable® event, Emily Ayers, MD, discussed the long-term results with loncastuximab in patients with diffuse large B-cell lymphoma and how this drug fared in the real-world setting in the second article of a 2-part series.
Read More
Fitting Loncastuximab Into the Current Landscape of R/R DLBCL
March 21st 2024During a Case-Based Roundtable® event, Emily Ayers, MD, discussed the current landscape for the treatment of patients with diffuse large B-cell lymphoma, the need for better risk stratification data, and what led to the approval of loncastuximab tesirine in the first article of a 2-part series.
Read More